Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), revealed on Monday that it has secured exclusive US marketing rights to Zevtera (ceftobiprole) from Swiss biopharmaceutical R&D company Basilea Pharmaceutica Ltd (SIX:BSLN).
Zevtera is an advanced-generation cephalosporin antibiotic approved by the US Food and Drug Administration (FDA) for treating various bacterial infections, including MRSA.
Innoviva plans to commercialise Zevtera in the United States in mid-2025.
This acquisition strengthens Innoviva's product portfolio and expands its presence in the infectious disease market.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy